Ipratropium bromide may increase risk for cardiovascular events
Saturday, January 9, 2010 - 22:21
in Health & Medicine
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure.